GlaxoSmithKline plc (GSK) Stake Lowered by Hilltop Holdings Inc.

Share on StockTwits

Hilltop Holdings Inc. lowered its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 61.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,869 shares of the pharmaceutical company’s stock after selling 45,066 shares during the quarter. Hilltop Holdings Inc.’s holdings in GlaxoSmithKline were worth $1,088,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GSK. Cubist Systematic Strategies LLC acquired a new position in shares of GlaxoSmithKline during the 1st quarter valued at about $416,000. Freestone Capital Holdings LLC lifted its position in shares of GlaxoSmithKline by 203.6% during the 1st quarter. Freestone Capital Holdings LLC now owns 268,601 shares of the pharmaceutical company’s stock worth $10,494,000 after buying an additional 180,124 shares during the period. Guggenheim Capital LLC lifted its position in shares of GlaxoSmithKline by 9.4% during the 1st quarter. Guggenheim Capital LLC now owns 154,102 shares of the pharmaceutical company’s stock worth $6,021,000 after buying an additional 13,262 shares during the period. Mariner LLC bought a new position in shares of GlaxoSmithKline during the 1st quarter worth approximately $267,000. Finally, LPL Financial LLC lifted its position in shares of GlaxoSmithKline by 159.3% during the 1st quarter. LPL Financial LLC now owns 561,798 shares of the pharmaceutical company’s stock worth $21,949,000 after buying an additional 345,106 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.

Shares of GlaxoSmithKline opened at $40.31 on Friday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 3.90, a current ratio of 0.61 and a quick ratio of 0.40. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $43.31. The firm has a market capitalization of $98.11 billion, a PE ratio of 14.00, a PEG ratio of 2.27 and a beta of 0.83.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.70 by ($0.02). The business had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. analysts expect that GlaxoSmithKline plc will post 2.79 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 12th. Shareholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share. The ex-dividend date of this dividend is Thursday, May 10th. This represents a $2.12 dividend on an annualized basis and a yield of 5.26%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 72.92%.

A number of research firms have recently weighed in on GSK. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Tuesday, April 3rd. DZ Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, June 14th. Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, April 9th. Finally, BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $40.21.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply